Compare IVVD & VNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IVVD | VNRX |
|---|---|---|
| Founded | 2020 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 437.1M | 31.9M |
| IPO Year | 2021 | 2012 |
| Metric | IVVD | VNRX |
|---|---|---|
| Price | $1.84 | $0.20 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $8.75 | $2.50 |
| AVG Volume (30 Days) | 1.8M | ★ 1.8M |
| Earning Date | 06-08-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 79.02 | 38.00 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $53,426,000.00 | $1,233,511.00 |
| Revenue This Year | $143.48 | $68.22 |
| Revenue Next Year | $25.40 | $382.75 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 110.47 | 59.10 |
| 52 Week Low | $0.46 | $0.17 |
| 52 Week High | $3.07 | $0.94 |
| Indicator | IVVD | VNRX |
|---|---|---|
| Relative Strength Index (RSI) | 53.71 | 39.55 |
| Support Level | $1.41 | $0.17 |
| Resistance Level | $2.01 | $0.27 |
| Average True Range (ATR) | 0.11 | 0.02 |
| MACD | 0.05 | 0.00 |
| Stochastic Oscillator | 65.06 | 30.00 |
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.